Suspensions of aspirin-treated, 32P-prelabelled, washed platelets containing ADP scavengers in the buffer were activated with either phorbol 12,13-dibutyrate (PdBu) ionophore A23187 induced shape change, aggregation, mobilization of Ca2+, rapid phosphorylation of the 20 and 47 kDa proteins and the formation of phosphatidic acid. Preincubation of platelets with PGI2 (500 ng/ml) inhibited platelet aggregation, but not shape change, Ca2+ mobilization or the phosphorylation of the 20 and 47 kDa proteins induced by Ca21 ionophore A23 187. The results indicate that PGI2, through activation of cyclic AMP-dependent kinases, inhibits platelet aggregation at steps distal to protein phosphorylation evoked by protein kinase C and Ca2+-dependent protein kinases.
INTRODUCTION
Most physiological platelet agonists stimulate inositol phospholipid hydrolysis by activation of phospholipase C [1] . Two products generated by this reaction have specific functions: 1,2-diacylglycerol activates protein kinase C (PKC), and inositol 1,4,5-trisphosphate mobilizes Ca2" from intracellular stores, leading to activation of Ca2+/calmodulin-dependent kinases such as myosin light-chain kinase (MLCK) [2] [3] [4] . Phorbol esters and Ca2" ionophores by-pass receptor activation and do not stimulate inositol phospholipid hydrolysis in platelets if the various positive-feedback mechanisms (ADP, endoperoxides/thromboxane A2) have been properly blocked [5, 6] . Phorbol ester and Ca2" ionophores activate platelets through different mechanisms and can be used specifically to probe the PKC-dependent pathway and the Ca2" pathway of platelet activation, respectively [7, 8] . Phorbol esters, by intercalation into the platelet membrane without mobilization of Ca2", translocate PKC from the cytosol to the membrane and induce the PKC-dependent phosphorylation of various proteins, such as the 47 kDa polypeptide and the 20 kDa myosin light chain [2, 9] . PKC phosphorylates the 20 kDa protein at sites different from those phosphorylated by MLCK [9] . Ca2" ionophores such as ionophore A23 187 activate platelets through Ca2" influx and Ca2" mobilization from intracellular stores [10, 11] . The increase in cytosolic Ca2" leads to the activation of Ca2+/calmodulin-dependent kinases, such as MLCK, which phosphorylates myosin light chain (20 kDa) , and to a Ca2"-dependent activation of PKC, which phosphorylates a 47 kDa protein [12, 13] .
Many studies indicate that phosphorylation of the 20 and 47 kDa proteins are closely related to platelet functional responses [1] : MLCK-dependent phosphorylation of myosin light chain may trigger shape change, whereas PKC-dependent phosphorylation of the 47 kDa polypeptide may regulate aggregation and secretion [14] [15] [16] .
Prostacyclin (PGI2) is the most powerful inhibitor of platelet function [17] . It increases cyclic AMP in human platelets, leading to activation of protein kinase A. In human platelets, protein kinase A phosphorylates proteins with molecular masses of 22, 24, 42, 50 and 130 kDa [18] [19] [20] [21] [22] . Cyclic AMP-dependent phosphorylation of the microsomal 22 kDa protein, recently named thrombolamban, stimulates Ca21 uptake into platelet membrane vesicles [23] [24] [25] [26] . From those results it is suggested that cyclic AMP acts through the stimulation of Ca2+ transport from the cytosol into the dense-tubular system. Such a mechanism of action might explain the rapid fall in cytoplasmic Ca2' and the reversal of protein phosphorylation that is observed when adenylate cyclase stimulators are added after the maximal platelet responses evoked by platelet stimuli [27] [28] [29] , but it does not explain the prevention of stimulus-induced platelet activation. It is currently assumed that the prevention of stimulus-induced platelet activation by cyclic AMP is caused by an inhibition of receptor-mediated phosphoinositide hydrolysis and subsequent PKC activation and Ca2+ mobilization [29] [30] [31] [32] .
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at steps distal to Ca2l mobilization [33] [34] [35] [36] . Also, it has been reported that the catalytic subunit of cyclic AMPdependent kinase phosphorylates the purified Ca2"/ calmodulin-dependent MLCK, thereby decreasing its ability to phosphorylate myosin light chain [37] . Furthermore, modest increments in platelet cyclic AMP have been reported to abolish platelet-activating-factorinduced aggregation and secretion, but to have little effect on phosphoinositide hydrolysis and elevation ofcytosolic Ca2" induced by platelet-activating factor [38] . The present study was undertaken to find out whether increasing platelet cyclic AMP could suppress aggregation by inhibiting PKC or Ca2"-dependent kinases involved in the activation of intact platelets.
EXPERIMENTAL Materials
Phorbol 12,13-dibutyrate (PdBu) and Ca2" ionophore A23187 were from Sigma. Stock solutions of PdBu were prepared in dimethyl sulphoxide, and ionophore A23187 was dissolved in ethanol. PGI2 was solubilized in glycine (1.88 mg/ml) and NaCl (1.47 mg/ml), and its pH adjusted with NaOH to 10.5. Indo-l/AM and quin-2/AM, both penta-acetoxylmethyl esters, were from Calbiochem (La Jolla, CA, U.S.A.) and were dissolved in dimethyl sulphoxide. All other materials were obtained as previously described [15, 16] .
Isolation and 32p labelling of human platelets Platelet-rich plasma from 160 ml of freshly drawn blood anticoagulated with 0.1 vol. of 3.8% (w/v) trisodium citrate was incubated with aspirin (1 mM) for 15 min at 37 'C. PGI2 (20 ng/ml) was then added, and platelets were pelleted by centrifugation at 800 g for 10 min. Platelets were resuspended in 3 ml of buffer prewarmed to 37 'C (pH 7.4) containing Hepes (20 mM), NaCl (138 mM), KCI (2.9 mM), MgCl2 ( [32] .
Phosphorylation of 32P-labelled proteins was measured after separation by SDS/polyacrylamide (12.5 00)-gel electrophoresis [39] . In control samples, 32P radioactivity ranged from 600 to 1500 c.p.m. for the 20 kDa protein, from 1000 to 4000 c.p.m. for the 47 kDa protein, and from 400 to 1000 c.p.m. for phosphatidic acid. All experiments shown are representative of at least three other experiments which gave similar results.
Measurement of Ca2" mobilization
Platelet-rich plasma from 160 ml of freshly drawn blood anticoagulated with trisodium citrate (0.38 %, w/v) was incubated with 5 /tM-Indo-1/AM dissolved in dimethyl sulphoxide and 1 /,tM-PGE, for 45 min at 37 'C.
Aspirin (1 mM) was then added, and incubation was continued for an additional 15 min. Platelets were pelleted by centrifugation and resuspended in 20 ml of buffer containing CaC12 (10 /LM) and apyrase (0.6 unit of ADPase/ml). Samples (I ml) of platelet suspension were prewarmed at 37 "C for 1 min, and Ca2+ measurements were performed in a Perkin-Elmer 512 double-beam fluorescence spectrophotometer. The emission wavelength was 390 nm and the excitation wavelength was 340 nm. F, Fmax, FMf and Fleak were recorded, and theintracellular Ca2" concentrations were calculated as in refs. [40] and [41] .
RESULTS

Effect of PGI2 on the stimulation of platelets by phorbol ester
Suspensions of aspirin-treated, 32P-prelabelled, washed platelets containing Ca2+ (10 /M) and apyrase (Figs. 2-5, 7) or phosphocreatine/creatine kinase (Figs. 1, 6, 8) in the buffer were exposed to PdBu. As with previous observations in platelet-rich plasma [15] , PdBu induced slow aggregation without prior shape change. Aggregation was decreased in the presence of EGTA (2 mM) and almost completely suppressed after preincubation of platelets with PGI2 (250 ng/ml) ( Fig. 1 ). Even at high concentrations (100 nM), PdBu did not increase platelet cytosolic Ca21 (Table 1) . Also, loading platelets with the Ca2+ chelator quin-2 enhanced platelet aggregation induced by PdBu (results not shown), whereas aggregation elicited by ionophore A23187 (see below), vasopressin and ADP was delayed.
PdBu-induced aggregation was associated with the PKC-dependent phosphorylation of several proteins (Fig. 2) . Phosphorylation of the 47 kDa protein preceded both aggregation and the phosphorylation of myosin light chain (20 kDa). Phosphorylation of the 20 kDa protein and platelet aggregation induced by PdBu showed similar kinetics. Addition of EGTA decreased aggregation, and decreased specifically 20 kDa protein phosphorylation elicited by PdBu (Fig. 3) . Omission of stirring of the platelet suspension eliminated platelet aggregation, but it did not affect 20 kDa protein phosphorylation elicited by PdBu (Fig. 3) . These results suggest a role for PKC-dependent myosin light-chain phosphorylation in platelet aggregation evoked by phorbol ester. However, studies using PGI2 showed that the PKC-dependent myosin light-chain (20 kDa) phosphorylation was not directly involved in platelet aggregation induced by PdBu. Preincubation of platelets with PGI2 inhibited aggregation in a dose-dependent manner, but it did not affect protein phosphorylation induced by PdBu, including the phosphorylation of the 20 kDa protein (Figs. 4-6 induced irreversible aggregation and a further increase in the 47 kDa-protein phosphorylation. In one experiment, the extent of protein phosphorylation was decreased in parallel with aggregation by preincubation of platelets with PGI2. However, the early increase in protein phosphorylation at 10 s was not affected by PGI2 (Fig. 7) (Table 1) . PGI2 also did not accelerate the return of elevated Ca21 concentration to basal values during the first 2 min after platelet stimulation with A23187 (results not shown). EGTA, which chelates extracellular Ca2+, and quin-2, which chelates intracellular Ca2 , or a combination of both delayed and diminished aggregation induced by ionophore A23187 (Fig. 9) . Interestingly, A23187 induced secretion of ATP with EGTA present, but not when it was absent. Similar findings have been reported previously, and might be explained by the relative impermeability of the platelet plasma membrane to calcium complexes of A23187 [42] . 
DISCUSSION
In the present study, PdBu and ionophore A23187 were used to stimulate separately the two known pathways of platelet activation, the PKC-and the Ca2+-dependent pathways respectively. Possible positive-feedback mechanisms were eliminated by irreversibly blocking platelet cyclo-oxygenase with aspirin and blocking the action of ADP by using ADP scavengers. Thus the effects of PdBu and ionophore A23187 on platelets can be considered direct actions not mediated or synergized by endoperoxide/thromboxane A2 or trace amounts of ADP.
PdBu, in the absence of any increase of cytosolic Ca2", evoked the phosphorylation of proteins with molecular masses of 20, 38 and 47 kDa. Dose-dependency and time courses of the 20 kDa myosin light-chain phosphorylation were different from those for the 47 kDa-protein phosphorylation, which agrees with findings from other laboratories [9, 43] . Interestingly, PdBu, phorbol 12-myristate 13-acetate and sn-1,2-dioctanoylglycerol stimulated the phosphorylation of proteins in the 38-41 kDa range, which may include the 41 kDa oi-subunit of G, (Fig. 2) [43, 44] . High concentrations (> 50 nM) of PdBu (which are supramaximal for the phosphorylation of the 47 kDa protein) were needed to observe a significant aggregation response. A close temporal relationship between phorbol ester-induced 20 kDa protein phosphorylation and platelet aggregation (Fig. 3) was found, suggesting a role for PKC-dependent myosin light-chain phosphorylation in inducing platelet aggregation. However, we found that preincubation of platelets with PGI2 completely suppressed aggregation without affecting the phosphorylation of the proteins stimulated by PdBu The resuspension platelet buffer contained phosphocreatine/creatine kinase instead of apyrase. Other conditions are the same as described in the legend to Fig. 1 . Symbols are as in Fig. 7 . This experiment is representative of another three that gave essentially similar results.
conclude that PdBu induces platelet aggregation through the PKC-dependent phosphorylation of specific proteins, [47] .
The data of the present study contrast somewhat with [15, 16] . The Ca2+-dependent phosphorylation of the 20 and 47 kDa proteins induced by ionophore A23187 was not inhibited by PGI2. In agreement with previous studies [10, 33, 34] , aggregation but not shape change was inhibited by PGI2. Since Ca2+ mobilization induced by ionophore A23187 was not inhibited by PGI2 (see also refs. [33, 34] ), these results indicate that aggregation is inhibited by PGI2 at steps distal to Ca2+-dependent phosphorylation of 20 and 47 kDa proteins. This result is somewhat unexpected: biochemical studies using purified proteins have demonstrated that protein kinase A phosphorylates MLCK, thereby diminishing its enzymic activity and decreasing its affinity for calmodulin [4, 37] . However, protein kinase A-dependent phosphorylation of MLCK has never been demonstrated in the intact cell.
The origin of phosphatidic acid formation after platelet activation with ionophore A23187 is not clear, because positive feedback activation of phospholipase C by cyclo-oxygenase products and ADP [6] had been eliminated in the present study. The increase in [32p]_ phosphatidic acid (-2-fold) observed was small compared with that with other stimuli, and might have escaped detection in earlier studies [6] [53, 54] .
Our study shows that PGI2, through activation of protein kinases A, inhibits platelet aggregation at steps distal to PKC and Ca2+-dependent protein phosphorylation. At present, it seems that cyclic AMP inhibits platelet activation at multiple steps: it inhibits phosphoinositide hydrolysis by phospholipase C [1] , fibrinogen receptor exposure [1] , and secretion and aggregation independently of Ca21 mobilization [33] [34] [35] [36] and independently of the activation of PKC-and Ca2+/ calmodulin-dependent kinases (the present study). The function of proteins phosphorylated by protein kinases A is still largely unknown.
